Update on terbinafine with a focus on dermatophytoses

Clinical, Cosmetic and Investigational Dermatology

Volumn 2, Issue , 2009, Pages 49-63

  Newland, Jason G ^a,b   Abdel Rahman, Susan M ^a,b  

^a CHILDREN S MERCY HOSPITAL   (United States)

^b UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

Author keywords

Allylamine; Antifungal; Microsporum; Tinea; Trichophyton

Indexed keywords

AMITRIPTYLINE; AMOROLFINE; AMPHOTERICIN B; CICLOPIROX; CIMETIDINE; DESIPRAMINE; FLUCONAZOLE; GRISEOFULVIN; IMIDAZOLE DERIVATIVE; ITRACONAZOLE; KETOCONAZOLE; NAFTIFINE; NORTRIPTYLINE; PLACEBO; PYRROLE DERIVATIVE; RIFAMPICIN; TERBINAFINE; TERFENADINE; TRIAZOLE DERIVATIVE; VENLAFAXINE; VORICONAZOLE;

ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS; AGEUSIA; AGRANULOCYTOSIS; ANOSMIA; APPETITE; AREA UNDER THE CURVE; ASPERGILLOSIS; AUTOIMMUNE HEPATITIS; CLINICAL TRIAL; DERMATOMYCOSIS; DERMATOMYOSITIS; DRESS SYNDROME; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG POTENTIATION; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC DISEASE; HUMAN; IRIDOCYCLITIS; LEUKOPENIA; LIVER TOXICITY; LOCAL SKIN REACTION; MAJOR CLINICAL STUDY; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NEUTROPENIA; ONYCHOMYCOSIS; OPTIC NERVE DISEASE; PANCYTOPENIA; PAPILLEDEMA; RECOMMENDED DRUG DOSE; REVIEW; SEPTIC SHOCK; SIDE EFFECT; SKIN CANDIDIASIS; SKIN LUPUS ERYTHEMATOSUS; STEVENS JOHNSON SYNDROME; TASTE; TASTE DISORDER; TINEA; TINEA CAPITIS; TINEA CORPORIS; TINEA CRURIS; TINEA IMBRICATA; TINEA PEDIS; TINEA VERSICOLOR; TONGUE; TOXIC EPIDERMAL NECROLYSIS; VERTIGO; VISION; WEIGHT GAIN;

EID: 77953438301     PISSN: None     EISSN: 11787015     Source Type: Journal    
DOI: None     Document Type: Review

References (214)

1. Brown M, Traynor M. Treatment of fungal nail infections. Drug Delivery Report. 2007(Spring/Summer):17-19.
2. Suh DC, Shin H, Raut M, Tavakkol A. Usage patterns of medical services and prescription drugs in patients with tinea capitis. J Am Acad Dermatol. 2004;50:86.
3. Birnbaum JE. Pharmacology of the allylamines. J Am Acad Dermatol. 1990;23(4 Pt 2):782-785.
4. Ganzinger U, Stutz A, Petranyi G, Stephen A. Allylamines: topical and oral treatment of dermatomycoses with a new class of antifungal agents. Acta Derm Venereol Suppl (Stockh). 1986;121:155-160.
5. Ryder NS. Specific inhibition of fungal sterol biosynthesis by SF 86-327, a new allylamine antimycotic agent. Antimicrob Agents Chemother. 1985;27(2):252-256.
6. Ryder NS. Terbinafine: mode of action and properties of the squalene epoxidase inhibition. Br J Dermatol. 1992;126 Suppl 39:2-7.
7. Ryder NS, Dupont MC. Inhibition of squalene epoxidase by allylamine antimycotic compounds. A comparative study of the fungal and mammalian enzymes. Biochem J. 1985;230(3):765-770.
8. Clayton YM. Relevance of broad-spectrum and fungicidal activity of antifungals in the treatment of dermatomycoses. Br J Dermatol. 1994;130 Suppl 43:7-8.
9. Dixon DM, Polak A. In vitro and in vivo drug studies with three agents of central nervous system phaeohyphomycosis. Chemotherapy. 1987;33(2):129-140.
10. Odds FC. Effects of temperature on anti-Candida activities of antifungal antibiotics. Antimicrob Agents Chemother. 1993;37(4):685-691.
11. Petranyi G, Meingassner JG, Mieth H. Activity of terbinafine in experimental fungal infections of laboratory animals. Antimicrob Agents Chemother. 1987;31(10):1558-1561.
12. Petranyi G, Meingassner JG, Mieth H. Antifungal activity of the allylamine derivative terbinafine in vitro. Antimicrob Agents Chemother. 1987;31(9):1365-1368.
13. Petranyi G, Ryder NS, Stutz A. Allylamine derivatives: new class of synthetic antifungal agents inhibiting fungal squalene epoxidase. Science. 1984;224(4654):1239-1241.
14. Schmitt HJ, Bernard EM, Andrade J, Edwards F, Schmitt B, Armstrong D. MIC and fungicidal activity of terbinafine against clinical isolates of Aspergillus spp. Antimicrob Agents Chemother. 1988;32(5):780-781.
15. Shadomy S, Espinel-Ingroff A, Gebhart RJ. In-vitro studies with SF 86-327, a new orally active allylamine derivative. Sabouraudia. 1985;23(2):125-132.
16. Venugopal PV, Venugopal TV. Antidermatophytic activity of allylamine derivatives. Indian J Pathol Microbiol. 1994;37(4):381-388.
17. Standards NCfCL. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved Standard. NCCLS document M38-A2. Wayne, PA: Clinical and Laboratory Standards Institute; 2008.
18. Goh CL, Tay YK, Ali KB, Koh MT, Seow CS. In vitro evaluation of griseofulvin, ketoconazole, and itraconazole against various dermatophytes in Singapore. Int J Dermatol. 1994;33(10):733-737.
19. Grant SM, Clissold SP. Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs. 1989;37(3):310-344.
20. Heel RC, Brogden RN, Carmine A, Morley PA, Speight TM, Avery GS. Ketoconazole: a review of its therapeutic efficacy in superficial and systemic fungal infections. Drugs. 1982;23(1-2):1-36.
21. Howard R, Aly R, Frieden I. Analysis of trychophyton tonsurans sensitivity to griseofulvin in vitro (abstract). Clin Res. 1993;41:420A.
22. Venugopal PV, Venugopal TV. Disk diffusion susceptibility testing of dermatophytes with allylamines. Int J Dermatol. 1994;33(10):730-732.
23. Venugopal PV, Venugopal TV. Antidermatophytic activity of garlic (Allium sativum) in vitro. Int J Dermatol. 1995;34(4):278-279.
24. da Silva Barros ME, de Assis Santos D, Hamdan JS. Evaluation of susceptibility of Trichophyton mentagrophytes and Trichophyton rubrum clinical isolates to antifungal drugs using a modified CLSI microdilution method (M38-A). J Med Microbiol. 2007;56(Pt 4):514-518.
25. Ghannoum MA, Wraith LA, Cai B, Nyirady J, Isham N. Susceptibility of dermatophyte isolates obtained from a large worldwide terbinafine tinea capitis clinical trial. Br J Dermatol. 2008;159(3):711-713.
26. Coelho LM, Aquino-Ferreira R, Maffei CM, Martinez-Rossi NM. In vitro antifungal drug susceptibilities of dermatophytes microconidia and arthroconidia. J Antimicrob Chemother. 2008;62(4):758-761.
27. Zeng YB, Qian YS, Ma L, Gu HN. Genome-wide expression profiling of the response to terbinafine in Candida albicans using a cDNA microarray analysis. Chin Med J (Engl). 2007;120(9):807-813.
28. Cervelatti EP, Fachin AL, Ferreira-Nozawa MS, Martinez-Rossi NM. Molecular cloning and characterization of a novel ABC transporter gene in the human pathogen Trichophyton rubrum. Med Mycol. 2006;44(2):141-147.
29. Graminha MA, Rocha EM, Prade RA, Martinez-Rossi NM. Terbinafine resistance mediated by salicylate 1-monooxygenase in Aspergillus nidulans. Antimicrob Agents Chemother. 2004;48(9):3530-3535.
30. Osborne CS, Hofbauer B, Favre B, Ryder NS. In vitro analysis of the ability of Trichophyton rubrum to become resistant to terbinafine. Antimicrob Agents Chemother. 2003;47(11):3634-3636.
31. Osborne CS, Leitner I, Favre B, Ryder NS. Amino acid substitution in Trichophyton rubrum squalene epoxidase associated with resistance to terbinafine. Antimicrob Agents Chemother. 2005;49(7):2840-2844.
32. Osborne CS, Leitner I, Hofbauer B, Fielding CA, Favre B, Ryder NS. Biological, biochemical, and molecular characterization of a new clinical Trichophyton rubrum isolate resistant to terbinafine. Antimicrob Agents Chemother. 2006;50(6):2234-2236.
33. Rocha EM, Almeida CB, Martinez-Rossi NM. Identification of genes involved in terbinafine resistance in Aspergillus nidulans. Lett Appl Microbiol. 2002;35(3):228-232.
34. Martinez-Rossi NM, Peres NT, Rossi A. Antifungal resistance mechanisms in dermatophytes. Mycopathologia. 2008;166(5-6):369-383.
35. Schuetzer-Muehlbauer M, Willinger B, Krapf G, Enzinger S, Presterl E, Kuchler K. The Candida albicans Cdr2p ATP-binding cassette (ABC) transporter confers resistance to caspofungin. Mol Microbiol. 2003;48(1):225-235.
36. Kohli A, Smriti, Mukhopadhyay K, Rattan A, Prasad R. In vitro low-level resistance to azoles in Candida albicans is associated with changes in membrane lipid fluidity and asymmetry. Antimicrob Agents Chemother. 2002;46(4):1046-1052.
37. Magaldi S, Mata S, Hartung C, Verde G, Deibis L, Roldan Y, et al. In vitro susceptibility of 137 Candida sp isolates from HIV positive patients to several antifungal drugs. Mycopathologia. 2001;149(2):63-68.
38. vanden Bossche H, Marichal P, Odds FC, Le Jeune L, Coene MC. Characterization of an azole-resistant Candida glabrata isolate. Antimicrob Agents Chemother. 1992;36(12):2602-2610.
39. Ryder NS, Leitner I. Activity of terbinafine against Aspergillus in vitro, in combination with amphotericin B or triazoles (Abstract E54). 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1996 Sept 15-18; New Orleans, LA. 1996.
40. Fothergill AW, Leitner I, Meingassner JG, Ryder NS, Rinaldi MG. Combination antifungal susceptibility testing of terbinafine and the triazoles fluconazole and itraconazole (Abstract E53). 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1996 September 15-18; New Orleans, LA. 1996.
41. Rodero L, Vitale R, Hochenfellner F, Canteos C, Davel G. In vitro activity of terbinafine in combination with triazole drugs against fluconazole resistant candida species (Abstract E56). . 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1996 September 15-18; New Orleans, LA. 1996.
42. Li L, Wang Z, Li R, Luo S, Sun X. In vitro evaluation of combination antifungal activity against Fusarium species isolated from ocular tissues of keratomycosis patients. Am J Ophthalmol. 2008;146(5): 724-728.
43. Abdel-Rahman SM, Herron J, Fallon-Friedlander S, Hauffe S, Horowitz A, Riviere GJ. Pharmacokinetics of terbinafine in young children treated for tinea capitis. Pediatr Infect Dis J. 2005;24(10):886-891.
44. Nejjam F, Zagula M, Cabiac MD, Guessous N, Humbert H, Lakhdar H. Pilot study of terbinafine in children suffering from tinea capitis: evaluation of efficacy, safety and pharmacokinetics. Br J Dermatol. 1995;132(1):98-105.
45. Jiang X, Wang N, Zhang ZJ, Tian Y, Chen Y. Pharmacokinetics and comparative bioavailability of two terbinafine hydrochloride formulations after single-dose administration in Chinese healthy subjects. Arzneimittelforschung. 2008;58(7):363-366.
46. Kovarik JM, Mueller EA, Zehender H, Denouel J, Caplain H, Millerioux L. Multiple-dose pharmacokinetics and distribution in tissue of terbinafine and metabolites. Antimicrob Agents Chemother. 1995;39(12):2738-2741.
47. Faergemann J, Zehender H, Denouel J, Millerioux L. Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally once per day for four weeks. Acta Derm Venereol. 1993;73(4):305-309.
48. Cramer J, Kshatriya B, Snoddy A. Skin pharmacokinetics of terbinafine in healthy subjects following once-daily application of 1% emulsion gel or 1% cream for 1, 5, or 7 days. American College of Clinical Pharmacy Annual Meeting; 2006 October 26; St. Louis, MO. 2006.
49. Denouell J, Burtin P, Kshatriya B, Snoddy A. Pharmacokinetics of terbinafine 1% emulsion gel in healthy volunteers and in patients with tinea cruris/corporis. American College of Clinical Pharmacy Annual Meeting; 2006; St. Louis, MO. 2006. p. October 26.
50. Kienzler JL, Queille-Roussel C, Mugglestone C, Ortonne JP, Larnier C. Stratum corneum pharmacokinetics of the anti-fungal drug, terbinafine, in a novel topical formulation, for single-dose application in dermatophytoses. Curr Med Res Opin. 2007;23(6):1293-1302.
51. Gupta AK, Sauder DN, Shear NH. Antifungal agents: an overview. Part II. J Am Acad Dermatol. 1994;30(6):911-33; quiz 34-6.
52. Jensen JC. Clinical pharmacokinetics of terbinafine (Lamisil). Clin Exp Dermatol. 1989;14(2):110-113.
53. Kovarik JM, Kirkesseli S, Humbert H, Grass P, Kutz K. Dose-proportional pharmacokinetics of terbinafine and its N-demethylated metabolite in healthy volunteers. Br J Dermatol. 1992;126 Suppl 39:8-13.
54. Hill S, Thomas R, Smith SG, Finlay AY. An investigation of the pharmacokinetics of topical terbinafine (Lamisil) 1% cream. Br J Dermatol. 1992;127(4):396-400.
55. Tanuma H, Doi M, Ohta Y, Nishiyama S, Katsuoka K, Kaneko S, et al. Usefulness of 1% terbinafine HCl (Lamisil) cream for hyperkeratotic-type tinea pedis and its transfer into the horny layer. Mycoses. 2000;43(11-12):417-432.
56. Jensen JC. Pharmacokinetics of Lamisil in humans. J Dermatol Treat. 1990;1 Suppl 2:15-18.
57. Ryder NS, Frank I. Interaction of terbinafine with human serum and serum proteins. J Med Vet Mycol. 1992;30(6):451-460.
58. Kikuchi I, Tanuma H, Morimoto K, Kawana S. Usefulness and pharmacokinetic study of oral terbinafine for hyperkeratotic type tinea pedis. Mycoses. 2008;51(1):7-13.
59. Humbert H, Cabiac MD, Denouel J, Kirkesseli S. Pharmacokinetics of terbinafine and of its five main metabolites in plasma and urine, following a single oral dose in healthy subjects. Biopharm Drug Dispos. 1995;16(8):685-694.
60. Abdel-Rahman SM, Marcucci K, Boge T, Gotschall RR, Kearns GL, Leeder JS. Potent inhibition of cytochrome P-450 2D6-mediated dextromethorphan O-demethylation by terbinafine. Drug Metab Dispos. 1999;27(7):770-775.
61. Back DJ, Tjia JF, Abel SM. Azoles, allylamines and drug metabolism. Br J Dermatol. 1992;126 Suppl 39:14-18.
62. Schuster I. The interaction of representative members from two classes of antimycotics - the azoles and the allylamines - with cytochromes P-450 in steroidogenic tissues and liver. Xenobiotica. 1985;15(6): 529-546.
63. Vickers AE, Sinclair JR, Zollinger M, Heitz F, Glanzel U, Johanson L, et al. Multiple cytochrome P-450s involved in the metabolism of terbinafine suggest a limited potential for drug-drug interactions. Drug Metab Dispos. 1999;27(9):1029-1038.
64. Abdel-Rahman SM, Gotschall RR, Kauffman RE, Leeder JS, Kearns GL. Investigation of terbinafine as a CYP2D6 inhibitor in vivo. Clin Pharmacol Ther. 1999;65(5):465-472.
65. Castberg I, Helle J, Aamo TO. Prolonged pharmacokinetic drug interaction between terbinafine and amitriptyline. Ther Drug Monit. 2005;27(5):680-682.
66. Hynninen VV, Olkkola KT, Bertilsson L, Kurkinen K, Neuvonen PJ, Laine K. Effect of terbinafine and voriconazole on the pharmacokinetics of the antidepressant venlafaxine. Clin Pharmacol Ther. 2008;83(2): 342-348.
67. Madani S, Barilla D, Cramer J, Wang Y, Paul C. Effect of terbinafine on the pharmacokinetics and pharmacodynamics of desipramine in healthy volunteers identified as cytochrome P450 2D6 (CYP2D6) extensive metabolizers. J Clin Pharmacol. 2002;42(11):1211-1218.
68. van der Kuy PH, Hooymans PM. Nortriptyline intoxication induced by terbinafine. BMJ. 1998;316(7129):441.
69. Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet. 2000;38(2):111-180.
70. Lamisil Package Insert. Sandoz Pharmaceutical Corporation. 1996.
71. Ahonen J, Olkkola KT, Neuvonen PJ. Effect of itraconazole and terbinafine on the pharmacokinetics and pharmacodynamics of midazolam in healthy volunteers. Br J Clin Pharmacol. 1995;40(3): 270-272.
72. Back DJ, Stevenson P, Tjia JF. Comparative effects of two antimycotic agents, ketoconazole and terbinafine on the metabolism of tolbutamide, ethinyloestradiol, cyclosporin and ethoxycoumarin by human liver microsomes in vitro. Br J Clin Pharmacol. 1989;28(2):166-170.
73. Seyffer R, Eichelbaum M, Jensen JC, Klotz U. Antipyrine metabolism is not affected by terbinafine, a new antifungal agent. Eur J Clin Pharmacol. 1989;37(3):231-233.
74. Shah IA, Whiting PH, Omar G, Ormerod AD, Burke MD. The effects of retinoids and terbinafine on the human hepatic microsomal metabolism of cyclosporin. Br J Dermatol. 1993;129(4):395-398.
75. Breckenridge A. Clinical significance of interactions with antifungal agents. Br J Dermatol. 1992;126 Suppl 39:19-22.
76. Zehender H, Cabiac MD, Denouel J, Faergemann J, Donatsch P, Kutz K, et al. Elimination kinetics of terbinafine from human plasma and tissue following multiple-dose administration, and comparison with 3 main metabolites. Drug Invest. 1994;8:203-210.
77. Odom R. Pathophysiology of dermatophyte infections. J Am Acad Dermatol. 1993;28(5 Pt 1):S2-S7.
78. Farag A, Taha M, Halim S. One-week therapy with oral terbinafine in cases of tinea cruris/corporis. Br J Dermatol. 1994;131(5):684-686.
79. Evans EG, Seaman RA, James IG. Short-duration therapy with terbinafine 1% cream in dermatophyte skin infections. Br J Dermatol. 1994;130(1):83-87.
80. Bonifaz A, Saul A. Comparative study between terbinafine 1% emulsion-gel versus ketoconazole 2% cream in tinea cruris and tinea corporis. Eur J Dermatol. 2000;10(2):107-109.
81. Budimulja U, Bramono K, Urip KS, Basuki S, Widodo G, Rapatz G, et al. Once daily treatment with terbinafine 1% cream (Lamisil) for one week is effective in the treatment of tinea corporis and cruris. A placebo-controlled study. Mycoses. 2001;44(7-8):300-306.
82. Greer DL, Jolly HW Jr. Treatment of tinea cruris with topical terbinafine. J Am Acad Dermatol. 1990;23(4 Pt 2):800-804.
83. Lebwohl M, Elewski B, Eisen D, Savin RC. Efficacy and safety of terbinafine 1% solution in the treatment of interdigital tinea pedis and tinea corporis or tinea cruris. Cutis. 2001;67(3):261-266.
84. Ledezma E, Lopez JC, Marin P, Romero H, Ferrara G, De Sousa L, et al. Ajoene in the topical short-term treatment of tinea cruris and tinea corporis in humans. Randomized comparative study with terbinafine. Arzneimittelforschung. 1999;49(6):544-547.
85. Millikan LE. Efficacy and tolerability of topical terbinafine in the treatment of tinea cruris. J Am Acad Dermatol. 1990;23(4 Pt 2):795-799.
86. Zaias N, Berman B, Cordero CN, Hernandez A, Jacobson C, Millikan L, et al. Efficacy of a 1-week, once-daily regimen of terbinafine 1% cream in the treatment of tinea cruris and tinea corporis. J Am Acad Dermatol. 1993;29(4):646-648.
87. Cole GW, Stricklin G. A comparison of a new oral antifungal, terbinafine, with griseofulvin as therapy for tinea corporis. Arch Dermatol. 1989;125(11):1537-1539.
88. del Palacio Hernandez A, Lopez Gomez S, Gonzalez Lastra F, Moreno Palancar P, Iglesias Diez L. A comparative double-blind study of terbinafine (Lamisil) and griseofulvin in tinea corporis and tinea cruris. Clin Exp Dermatol. 1990;15(3):210-216.
89. Voravutinon V. Oral treatment of tinea corporis and tinea cruris with terbinafine and griseofulvin: a randomized double blind comparative study. J Med Assoc Thai. 1993;76(7):388-393.
90. Budimulja U, Kuswadji K, Bramono S, Basuki J, Judanarso LS, Untung S, et al. A double-blind, randomized, stratified controlled study of the treatment of tinea imbricata with oral terbinafine or itraconazole. Br J Dermatol. 1994;130 Suppl 43:29-31.
91. Shrum JP, Millikan LE, Bataineh O. Superficial fungal infections in the tropics. Dermatol Clin. 1994;12(4):687-693.
92. Elewski B, Nagashima-Whalen L. Superficial fungal infections of the skin. In: Hoeprich PD, Jordan MC, Ronald AR, editors. Infectious Diseases- A treatise of infectious processes. 5th ed. Philadelphia, PA: JB Lippincott Company; 1994. p. 1029-1049.
93. Hollmen KA, Kinnunen T, Kiistala U, Vaananen A, Saarelainen IO, De CC, et al. Efficacy and tolerability of terbinafine 1% emulsion gel in patients with tinea pedis. J Eur Acad Dermatol Venereol. 2002; 16(1):87-88.
94. James IG, Loria-Kanza Y, Jones TC. Short-duration topical treatment of tinea pedis using terbinafine emulsion gel: results of a dose-ranging clinical trial. J Dermatolog Treat. 2007;18(3):163-8.
95. Korting HC, Tietz HJ, Brautigam M, Mayser P, Rapatz G, Paul C. One week terbinafine 1% cream (Lamisil) once daily is effective in the treatment of interdigital tinea pedis: a vehicle controlled study. LAS-INT-06 Study Group. Med Mycol. 2001;39(4):335-340.
96. Ledezma E, Marcano K, Jorquera A, De Sousa L, Padilla M, Pulgar M, et al. Efficacy of ajoene in the treatment of tinea pedis: a double-blind and comparative study with terbinafine. J Am Acad Dermatol. 2000;43(5 Pt 1):829-832.
97. Leenutaphong V, Niumpradit N, Tangwiwat S, Sritaveesuwan R, Muanprasat C. Double-blind study of the efficacy of 1 week topical terbinafine cream compared to 4 weeks miconazole cream in patients with tinea pedis. J Med Assoc Thai. 1999;82(10):1006-1010.
98. Patel A, Brookman SD, Bullen MU, Marley J, Ellis DH, Williams T, et al. Topical treatment of interdigital tinea pedis: terbinafine compared with clotrimazole. Australas J Dermatol. 1999;40(4):197-200.
99. Schopf R, Hettler O, Brautigam M, Weidinger G, Kaben U, Mayser P, et al. Efficacy and tolerability of terbinafine 1% topical solution used for 1 week compared with 4 weeks clotrimazole 1% topical solution in the treatment of interdigital tinea pedis: a randomized, double-blind, multi-centre, 8-week clinical trial. Mycoses. 1999;42(5-6): 415-420.
100. de Chauvin MF, Viguie-Vallanet C, Kienzler JL, Larnier C. Novel, single-dose, topical treatment of tinea pedis using terbinafine: results of a dose-finding clinical trial. Mycoses. 2008;51(1):1-6.
101. Ortonne JP, Korting HC, Viguie-Vallanet C, Larnier C, Savaluny E. Efficacy and safety of a new single-dose terbinafine 1% formulation in patients with tinea pedis (athlete's foot): a randomized, double-blind, placebo-controlled study. J Eur Acad Dermatol Venereol. 2006;20(10): 1307-1313.
102. Savin R. Successful treatment of chronic tinea pedis (moccasin type) with terbinafine (Lamisil). Clin Exp Dermatol. 1989;14(2):116-119.
103. Savin RC, Zaias N. Treatment of chronic moccasin-type tinea pedis with terbinafine: a double-blind, placebo-controlled trial. J Am Acad Dermatol. 1990;23(4 Pt 2):804-807.
104. De Keyser P, De Backer M, Massart DL, Westelinck KJ. Two-week oral treatment of tinea pedis, comparing terbinafine (250 mg/day) with itraconazole (100 mg/day): a double-blind, multicentre study. Br J Dermatol. 1994;130 Suppl 43:22-25.
105. Hay RJ, McGregor JM, Wuite J, Ryatt KS, Ziegler C, Clayton YM. A comparison of 2 weeks of terbinafine 250 mg/day with 4 weeks of itraconazole 100 mg/day in plantar-type tinea pedis. Br J Dermatol. 1995;132(4):604-608.
106. Scher RK. Onychomycosis is more than a cosmetic problem. Br J Dermatol. 1994;130 Suppl 43:15.
107. Degreef H. Onychomycosis. Br J Clin Pract Suppl. 1990;71:91-97.
108. Midgley G, Moore MK, Cook JC, Phan QG. Mycology of nail disorders. J Am Acad Dermatol. 1994;31(3 Pt 2):S68-74.
109. Baudraz-Rosselet F, Rakosi T, Wili PB, Kenzelmann R. Treatment of onychomycosis with terbinafine. Br J Dermatol. 1992;126 Suppl 39:40-46.
110. Farkas B, Paul C, Dobozy A, Hunyadi J, Horvath A, Fekete G. Terbinafine (Lamisil) treatment of toenail onychomycosis in patients with insulin-dependent and non-insulin-dependent diabetes mellitus: a multicentre trial. Br J Dermatol. 2002;146(2):254-260.
111. Goodfield MJ, Andrew L, Evans EG. Short term treatment of dermatophyte onychomycosis with terbinafine. BMJ. 1992;304(6835):1151-1154.
112. Pollak R, Billstein SA. Efficacy of terbinafine for toenail onychomycosis. A multicenter trial of various treatment durations. J Am Podiatr Med Assoc. 2001;91(3):127-131.
113. Watson A, Marley J, Ellis D, Williams T. Terbinafine in onychomycosis of the toenail: a novel treatment protocol. J Am Acad Dermatol. 1995;33(5 Pt 1):775-779.
114. Zaias N, Serrano L. The successful treatment of finger Trichophyton rubrum onychomycosis with oral terbinafine. Clin Exp Dermatol. 1989;14(2):120-123.
115. Gupta AK, Gregurek-Novak T. Efficacy of itraconazole, terbinafine, fluconazole, griseofulvin and ketoconazole in the treatment of Scopulariopsis brevicaulis causing onychomycosis of the toes. Dermatology. 2001;202(3):235-238.
116. Warshaw EM, Nelson D, Carver SM, Zielke GR, Webster N, Lederle FA, et al. A pilot evaluation of pulse itraconazole vs terbinafine for treatment of Candida toenail onychomycosis. Int J Dermatol. 2005;44(9):785-788.
117. Wong CK, Cho YL. Very short duration therapy with oral terbinafine for fingernail onychomycosis. Br J Dermatol. 1995;133(2):329-331.
118. Albanese G, Di Cintio R, Martini C, Nicoletti A. Short therapy for tinea unguium with terbinafine: four different courses of treatment. Mycoses. 1995;38(5-6):211-214.
119. Jennings MB, Pollak R, Harkless LB, Kianifard F, Tavakkol A. Treatment of toenail onychomycosis with oral terbinafine plus aggressive debridement: IRON-CLAD, a large, randomized, open-label, multicenter trial. J Am Podiatr Med Assoc. 2006;96(6):465-473.
120. Avner S, Nir N, Henri T. Combination of oral terbinafine and topical ciclopirox compared to oral terbinafine for the treatment of onychomycosis. J Dermatolog Treat. 2005;16(5-6):327-330.
121. Baran R. Topical amorolfine for 15 months combined with 12 weeks of oral terbinafine, a cost-effective treatment for onychomycosis. Br J Dermatol. 2001;145 Suppl 60:15-19.
122. Baran R, Sigurgeirsson B, de Berker D, Kaufmann R, Lecha M, Faergemann J, et al. A multicentre, randomized, controlled study of the efficacy, safety and cost-effectiveness of a combination therapy with amorolfine nail lacquer and oral terbinafine compared with oral terbinafine alone for the treatment of onychomycosis with matrix involvement. Br J Dermatol. 2007;157(1):149-157.
123. Gupta AK. Ciclopirox topical solution, 8% combined with oral terbinafine to treat onychomycosis: a randomized, evaluator-blinded study. J Drugs Dermatol. 2005;4(4):481-485.
124. Sigurgeirsson B, Elewski BE, Rich PA, Opper C, Cai B, Nyirady J, et al. Intermittent versus continuous terbinafine in the treatment of toenail onychomycosis: a randomized, double-blind comparison. J Dermatolog Treat. 2006;17(1):38-44.
125. Warshaw EM, Fett DD, Bloomfield HE, Grill JP, Nelson DB, Quintero V, et al. Pulse versus continuous terbinafine for onychomycosis: a randomized, double-blind, controlled trial. J Am Acad Dermatol. 2005;53(4):578-584.
126. Nakano N, Hiruma M, Shiraki Y, Chen X, Porgpermdee S, Ikeda S. Combination of pulse therapy with terbinafine tablets and topical terbinafine cream for the treatment of dermatophyte onychomycosis: a pilot study. J Dermatol. 2006;33(11):753-758.
127. Jaiswal A, Sharma RP, Garg AP. An open randomized comparative study to test the efficacy and safety of oral terbinafine pulse as a monotherapy and in combination with topical ciclopirox olamine 8% or topical amorolfine hydrochloride 5% in the treatment of onychomycosis. Indian J Dermatol Venereol Leprol. 2007;73(6): 393-396.
128. Takahata Y, Hiruma M, Shiraki Y, Tokuhisa Y, Sugita T, Muto M. Treatment of dermatophyte onychomycosis with three pulses of terbinafine (500 mg day for a week). Mycoses. 2009;52(1):72-76.
129. Faergemann J, Anderson C, Hersle K, Hradil E, Nordin P, Kaaman T, et al. Double-blind, parallel-group comparison of terbinafine and griseofulvin in the treatment of toenail onychomycosis. J Am Acad Dermatol. 1995;32(5 Pt 1):750-753.
130. Haneke E, Tausch I, Brautigam M, Weidinger G, Welzel D. Short-duration treatment of fingernail dermatophytosis: a randomized, double-blind study with terbinafine and griseofulvin. LAGOS III Study Group. J Am Acad Dermatol. 1995;32(1):72-77.
131. Hofmann H, Brautigam M, Weidinger G, Zaun H. Treatment of toenail onychomycosis. A randomized, double-blind study with terbinafine and griseofulvin. LAGOS II Study Group. Arch Dermatol. 1995;131(8):919-922.
132. Arenas R, Dominguez-Cherit J, Fernandez LM. Open randomized comparison of itraconazole versus terbinafine in onychomycosis. Int J Dermatol. 1995;34(2):138-143.
133. Brautigam M, Nolting S, Schopf RE, Weidinger G. Randomised double blind comparison of terbinafine and itraconazole for treatment of toenail tinea infection. Seventh Lamisil German Onychomycosis Study Group. BMJ. 1995;311(7010):919-922.
134. Degreef H, del Palacio A, Mygind S, Ginter G, Pinto Soares A, Zuluaga de Cadena A. Randomized double-blind comparison of short-term itraconazole and terbinafine therapy for toenail onychomycosis. Acta Derm Venereol. 1999;79(3):221-223.
135. Arca E, Tastan HB, Akar A, Kurumlu Z, Gur AR. An open, randomized, comparative study of oral fluconazole, itraconazole and terbinafine therapy in onychomycosis. J Dermatolog Treat. 2002;13(1):3-9.
136. Gupta AK, Gover MD, Lynde CW. Pulse itraconazole vs continuous terbinafine for the treatment of dermatophyte toenail onychomycosis in patients with diabetes mellitus. J Eur Acad Dermatol Venereol. 2006;20(10):1188-1193.
137. Kejda J. Itraconazole pulse therapy vs continuous terbinafine dosing for toenail onychomycosis. Postgrad Med. 1999; Spec No:12-15.
138. Mishra M, Panda P, Tripathy S, Sengupta S, Mishra K. An open randomized comparative study of oral itraconazole pulse and terbinafine pulse in the treatment of onychomycosis. Indian J Dermatol Venereol Leprol. 2005;71(4):262-266.
139. Sigurgeirsson B, Billstein S, Rantanen T, Ruzicka T, di Fonzo E, Vermeer BJ, et al. L.I.ON. Study: efficacy and tolerability of continuous terbinafine (Lamisil) compared to intermittent itraconazole in the treatment of toenail onychomycosis. Lamisil vs Itraconazole in Onychomycosis. Br J Dermatol. 1999;141 Suppl 56:5-14.
140. Heikkila H, Stubb S. Long-term results in patients with onychomycosis treated with terbinafine or itraconazole. Br J Dermatol. 2002;146(2):250-253.
141. Sigurgeirsson B, Olafsson JH, Steinsson JB, Paul C, Billstein S, Evans EG. Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: a 5-year blinded prospective follow-up study. Arch Dermatol. 2002;138(3):353-357.
142. Havu V, Heikkila H, Kuokkanen K, Nuutinen M, Rantanen T, Saari S, et al. A double-blind, randomized study to compare the efficacy and safety of terbinafine (Lamisil) with fluconazole (Diflucan) in the treatment of onychomycosis. Br J Dermatol. 2000;142(1):97-102.
143. Baran R, de Doncker P. Lateral edge nail involvement indicates poor prognosis for treating onychomycosis with the new systemic antifungals. Acta Derm Venereol. 1996;76(1):82-83.
144. Sigurgeirsson B, Paul C, Curran D, Evans EG. Prognostic factors of mycological cure following treatment of onychomycosis with oral antifungal agents. Br J Dermatol. 2002;147(6):1241-1243.
145. Sommer S, Sheehan-Dare RA, Goodfield MJ, Evans EG. Prediction of outcome in the treatment of onychomycosis. Clin Exp Dermatol. 2003;28(4):425-428.
146. Roberts DT, Evans EG. Subungual dermatophytoma complicating dermatophyte onychomycosis. Br J Dermatol. 1998;138(1):189-190.
147. O'Brien JM. Common skin problems of infancy, childhood, and adolescence. Prim Care. 1995;22(1):99-115.
148. Abdel-Rahman SM, Nahata MC, Powell DA. Response to initial griseofulvin therapy in pediatric patients with tinea capitis. Ann Pharmacother. 1997;31(4):406-410.
149. Bronson DM, Desai DR, Barsky S, Foley SM. An epidemic of infection with Trichophyton tonsurans revealed in a 20-year survey of fungal infections in Chicago. J Am Acad Dermatol. 1983;8(3):322-330.
150. Laude TA, Shah BR, Lynfield Y. Tinea capitis in Brooklyn. Am J Dis Child. 1982;136(12):1047-1050.
151. Prevost E. Nonfluorescent tinea capitis in Charleston, SC. A diagnostic problem. JAMA. 1979;242(16):1765-1767.
152. Friedlander SF, Aly R, Krafchik B, Blumer J, Honig P, Stewart D, et al. Terbinafine in the treatment of Trichophyton tinea capitis: a randomized, double-blind, parallel-group, duration-finding study. Pediatrics. 2002;109(4):602-607.
153. Hamm H, Schwinn A, Brautigam M, Weidinger G. Short duration treatment with terbinafine for tinea capitis caused by Trichophyton or Microsporum species. The Study Group. Br J Dermatol. 1999;140(3):480-482.
154. Haroon TS, Hussain I, Mahmood A, Nagi AH, Ahmad I, Zahid M. An open clinical pilot study of the efficacy and safety of oral terbinafine in dry non-inflammatory tinea capitis. Br J Dermatol. 1992;126 Suppl 39:47-50.
155. Krafchik B, Pelletier J. An open study of tinea capitis in 50 children treated with a 2-week course of oral terbinafine. J Am Acad Dermatol. 1999;41(1):60-63.
156. Aste N, Pau M. Tinea capitis caused by Microsporum canis treated with terbinafine. Mycoses. 2004;47(9-10):428-430.
157. Koumantaki E, Kakourou T, Rallis E, Riga P, Georgalla S. Doubled dose of oral terbinafine is required for Microsporum canis tinea capitis. Pediatr Dermatol. 2001;18(4):339-342.
158. Silm H, Karelson M. Terbinafine: efficacy and tolerability in young children with tinea capitis due to Microsporum canis. J Eur Acad Dermatol Venereol. 2002;16(3):228-230.
159. Alvi KH, Iqbal N, Khan KA, Haroon TS, Hussain I, Aman S, et al. A randomized double-blind trial of the efficacy and tolerability of terbinafine once daily compared to griseofulvin once daily in the treatment of tinea capitis. In: Shuster S, Jafary MH, editors. Royal Society of Medicine Services International Congress Series; 1992. p. 35-40.
160. Caceres-Rios H, Rueda M, Ballona R, Bustamante B. Comparison of terbinafine and griseofulvin in the treatment of tinea capitis. J Am Acad Dermatol. 2000;42(1 Pt 1):80-84.
161. Fuller LC, Smith CH, Cerio R, Marsden RA, Midgley G, Beard AL, et al. A randomized comparison of 4 weeks of terbinafine vs 8 weeks of griseofulvin for the treatment of tinea capitis. Br J Dermatol. 2001;144(2):321-327.
162. Lipozencic J, Skerlev M, Orofino-Costa R, Zaitz VC, Horvath A, Chouela E, et al. A randomized, double-blind, parallel-group, duration-finding study of oral terbinafine and open-label, high-dose griseofulvin in children with tinea capitis due to Microsporum species. Br J Dermatol. 2002;146(5):816-823.
163. Ungpakorn R, Ayutyanont T, Reangchainam S, Supanya S. Treatment of Microsporum spp. tinea capitis with pulsed oral terbinafine. Clin Exp Dermatol. 2004;29(3):300-303.
164. Gupta AK, Adam P, Dlova N, Lynde CW, Hofstader S, Morar N, et al. Therapeutic options for the treatment of tinea capitis caused by Trichophyton species: griseofulvin versus the new oral antifungal agents, terbinafine, itraconazole, and fluconazole. Pediatr Dermatol. 2001;18(5):433-438.
165. Elewski BE, Caceres HW, DeLeon L, El Shimy S, Hunter JA, Korotkiy N, et al. Terbinafine hydrochloride oral granules versus oral griseofulvin suspension in children with tinea capitis: results of two randomized, investigator-blinded, multicenter, international, controlled trials. J Am Acad Dermatol. 2008;59(1):41-54.
166. Faergemann J, Zehender H, Boukhabza A, Smith SG, Jones TC. A double-blind comparison of levels of terbinafine and itraconazole in plasma, skin, sebum, hair and nails during and after oral medication. Acta Derm Venereol. 1997;77(1):74-76.
167. Jung EG, Haas PJ, Brautigam M, Weidinger G. Systemic treatment of skin candidosis: a randomized comparison of terbinafine and ketoconazole. Mycoses. 1994;37(9-10):361-365.
168. Gianni C, Romano C. Clinical and histological aspects of toenail onychomycosis caused by Aspergillus spp: 34 cases treated with weekly intermittent terbinafine. Dermatology. 2004;209(2):104-110.
169. Li DM, Xiu DR, Li RY, Samson RA, de Hoog GS, Wang DL. Aspergillus flavus myositis in a patient after liver transplantation. Clin Transplant. 2008;22(4):508-511.
170. Krishnan-Natesana S, Chandrasekara PH, Manavathua EK, Revankar SG. Successful treatment of primary cutaneous Aspergillus ustus infection with surgical debridement and a combination of voriconazole and terbinafine. Diagn Microbiol Infect Dis. 2008;62(4):443-446.
171. Esterre P, Inzan CK, Ramarcel ER, Andriantsimahavandy A, Ratsioharana M, Pecarrere JL, et al. Treatment of chromomycosis with terbinafine: preliminary results of an open pilot study. Br J Dermatol. 1996;134 Suppl 46:33-36; discussion 40.
172. Xibao Z, Changxing L, Quan L, Yuqing H. Treatment of chromoblastomycosis with terbinafine: a report of four cases. J Dermatolog Treat. 2005;16(2):121-124.
173. Bryan CS, Smith CW, Berg DE, Karp RB. Curvularia lunata endocarditis treated with terbinafine: case report. Clin Infect Dis. 1993;16(1):30-32.
174. Zhang J, Xi L, Lu C, Li X, Xie T, Zhang H, et al. Successful treatment for chromoblastomycosis caused by Fonsecae monophona: a report of three cases in Guangdong, China. Mycoses. 2009;52(2):176-181.
175. Anderson KL, Mitra S, Salouti R, Pham TA, Taylor HR. Fungal keratitis caused by Paecilomyces lilacinus associated with a retained intracorneal hair. Cornea. 2004;23(5):516-521.
176. Ford JG, Agee S, Greenhaw ST. Successful medical treatment of a case of Paecilomyces lilacinus keratitis. Cornea. 2008;27(9):1077-1079.
177. Ollague JM, de Zurita AM, Calero G. Paracoccidioidomycosis (South American blastomycosis) successfully treated with terbinafine: first case report. Br J Dermatol. 2000;143(1):188-191.
178. Gip L. Terbinafine for black piedra. Lancet. 1993;341(8853):1164.
179. Wong PK, Ching WT, Kwon-Chung KJ, Meyer RD. Disseminated Phialophora parasitica infection in humans: case report and review. Rev Infect Dis. 1989;11(5):770-775.
180. Coskun B, Saral Y, Akpolat N, Ataseven A, Cicek D. Sporotrichosis successfully treated with terbinafine and potassium iodide: case report and review of the literature. Mycopathologia. 2004;158(1):53-56.
181. Hull PR, Vismer HF. Treatment of cutaneous sporotrichosis with terbinafine. Br J Dermatol. 1992;126 Suppl 39:51-55.
182. Finlay AY. Global overview of Lamisil. Br J Dermatol. 1994; 130 Suppl 43:1-3.
183. Pollak R, Billstein SA. Safety of oral terbinafine for toenail onychomycosis. J Am Podiatr Med Assoc. 1997;87(12):565-570.
184. Villars V, Jones TC. Clinical efficacy and tolerability of terbinafine (Lamisil) - a new topical and systemic fungicidal drug for treatment of dermatomycoses. Clin Exp Dermatol. 1989;14(2):124-127.
185. De Backer M, De Vroey C, Lesaffre E, Scheys I, De Keyser P. Twelve weeks of continuous oral therapy for toenail onychomycosis caused by dermatophytes: a double-blind comparative trial of terbinafine 250 mg/day versus itraconazole 200 mg/day. J Am Acad Dermatol. 1998;38(5 Pt 3):S57-S63.
186. Drake LA, Shear NH, Arlette JP, Cloutier R, Danby FW, Elewski BE, et al. Oral terbinafine in the treatment of toenail onychomycosis: North American multicenter trial. J Am Acad Dermatol. 1997; 37(5 Pt 1):740-745.
187. Chang CH, Young-Xu Y, Kurth T, Orav JE, Chan AK. The safety of oral antifungal treatments for superficial dermatophytosis and onychomycosis: a meta-analysis. Am J Med. 2007;120(9):791-798.
188. Hall M, Monka C, Krupp P, O'Sullivan D. Safety of oral terbinafine: results of a postmarketing surveillance study in 25,884 patients. Arch Dermatol. 1997;133(10):1213-1219.
189. Agarwal K, Manas DM, Hudson M. Terbinafine and fulminant hepatic failure. N Engl J Med. 1999;340(16):1292-1293.
190. Fernandes NF, Geller SA, Fong TL. Terbinafine hepatotoxicity: case report and review of the literature. Am J Gastroenterol. 1998;93(3):459-460.
191. Brown PC. NDA 22-047; Lamisil® (terbinafine hydrochloride) Oral Granules. In: Administration FaD, editor; 2007.
192. Lowe G, Green C, Jennings P. Hepatitis associated with terbinafine treatment. BMJ. 1993;306(6872):248.
193. Paredes AH, Lewis JH. Terbinafine-induced acute autoimmune hepatitis in the setting of hepatitis B virus infection. Ann Pharmacother. 2007;41(5):880-884.
194. Committee ADRA. Terbinafine and blood dyscrasias. Australian Adverse Drug Reactions Bulletin. 2004;23:19.
195. Beltraminelli HS, Lerch M, Arnold A, Bircher AJ, Haeusermann P. Acute generalized exanthematous pustulosis induced by the antifungal terbinafine: case report and review of the literature. Br J Dermatol. 2005;152(4):780-783.
196. Hivnor CM, Hudkins ML, Bonner B. Terbinafine-induced subacute cutaneous lupus erythematosus. Cutis. 2008;81(2):156-157.
197. Magro CM, Schaefer JT, Waldman J, Knight D, Seilstad K, Hearne D. Terbinafine-induced dermatomyositis: a case report and literature review of drug-induced dermatomyositis. J Cutan Pathol. 2008;35(1):74-81.
198. Carstens J, Wendelboe P, Sogaard H, Thestrup-Pedersen K. Toxic epidermal necrolysis and erythema multiforme following therapy with terbinafine. Acta Derm Venereol. 1994;74(5):391-392.
199. Gupta AK, Porges AJ. Hypersensitivity syndrome reaction to oral terbinafine. Australas J Dermatol. 1998;39(3):171-172.
200. Kovacs MJ, Alshammari S, Guenther L, Bourcier M. Neutropenia and pancytopenia associated with oral terbinafine. J Am Acad Dermatol. 1994;31(5 Pt 1):806.
201. Rzany B, Mockenhaupt M, Gehring W, Schopf E. Stevens-Johnson syndrome after terbinafine therapy. J Am Acad Dermatol. 1994;30(3):509.
202. Todd P, Halpern S, Munro DD. Oral terbinafine and erythema multiforme. Clin Exp Dermatol. 1995;20(3):247-248.
203. Wach F, Stolz W, Hein R, Landthaler M. Severe erythema anulare centrifugum-like psoriatic drug eruption induced by terbinafine. Arch Dermatol. 1995;131(8):960-961.
204. Beutler M, Hartmann K, Kuhn M, Gartmann J. Taste disorders and terbinafine. BMJ. 1993;307(6895):26.
205. Bong JL, Lucke TW, Evans CD. Persistent impairment of taste resulting from terbinafine. Br J Dermatol. 1998;139(4):747-748.
206. Doty RL, Haxel BR. Objective assessment of terbinafine-induced taste loss. Laryngoscope. 2005;115(11):2035-2037.
207. Duxbury AJ, Oliver RJ, Pemberton MN. Persistent impairment of taste associated with terbinafine. Br Dent J. 2000;188(6):295-296.
208. Juhlin L. Loss of taste and terbinafine. Lancet. 1992;339(8807):1483.
209. Lemont H, Sabo M. Terbinafine-associated taste disturbance with normal taste threshold scores. J Am Podiatr Med Assoc. 2001;91(10): 540-541.
210. Ottervanger JP, Stricker BH. Loss of taste and terbinafine. Lancet. 1992;340(8821):728.
211. Stricker BH, Van Riemsdijk MM, Sturkenboom MC, Ottervanger JP. Taste loss to terbinafine: a case-control study of potential risk factors. Br J Clin Pharmacol. 1996;42(3):313-318.
212. Gupta AK, Gonder JR, Shear NH, Dilworth GR. The development of green vision in association with terbinafine therapy. Arch Dermatol. 1996;132(7):845-846.
213. Price T, Stallman J, Dretler RH. Anterior uveitis in a patient with AIDS who was treated with terbinafine for oral candidiasis: a potential drug-induced reaction. Clin Infect Dis. 1997;25(3):752-753.
214. Yulek F, Cagil N, Cakmak HB, Akcay EK, Simsek S, Kansu T. Bilateral anterior optic neuropathy associated with use of terbinafine. Clin Experiment Ophthalmol. 2008;36(5):488-489.